Cover Image
市場調查報告書

肝硬化 : 開發中產品分析

Liver Cirrhosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213038
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
肝硬化 : 開發中產品分析 Liver Cirrhosis - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 86 Pages
簡介

所謂肝硬化是指由於各種肝臟疾病(肝炎·慢性酒精中毒等)所造成的肝臟疤痕組織狀態。由於疤痕組織造成正常結構受損,更進一步對肝臟內血液流通造成不良影響。主要的症狀有食慾不振和皮膚發癢,體重減少,疲勞感,噁心等。主要的治療方法有肝臟移植手術等。

本報告提供全球各國治療肝硬化所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查。

目錄

簡介

  • 分析範圍

肝硬化概要

治療藥的開發

  • 肝硬化開發中產品:概要
  • 肝硬化開發中產品:比較分析

各企業開發中的肝硬化治療藥

大學/研究機關研究中的肝硬化治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

肝硬化治療藥:開發中的產品一覽(各企業)

肝硬化治療藥:研究中的產品一覽(各大學/研究機關)

肝硬化治療藥的開發企業

  • Conatus Pharmaceuticals Inc.
  • Digna Biotech, S.L.
  • Galectin Therapeutics, Inc.
  • Human Stem Cells Institute
  • Nimbus Therapeutics, LLC
  • Ocera Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • S-Evans Biosciences, Inc.
  • Stelic Institute & Co., Inc.

肝硬化:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

肝硬化治療藥:開發暫停的產品

肝硬化治療藥:開發中止的產品

肝硬化相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8434IDB

Summary

Global Markets Direct's, 'Liver Cirrhosis - Pipeline Review, H2 2016', provides an overview of the Liver Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
  • The report reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Liver Cirrhosis therapeutics and enlists all their major and minor projects
  • The report assesses Liver Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Liver Cirrhosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Liver Cirrhosis Overview
  • Therapeutics Development
    • Pipeline Products for Liver Cirrhosis - Overview
    • Pipeline Products for Liver Cirrhosis - Comparative Analysis
  • Liver Cirrhosis - Therapeutics under Development by Companies
  • Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes
  • Liver Cirrhosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Liver Cirrhosis - Products under Development by Companies
  • Liver Cirrhosis - Products under Investigation by Universities/Institutes
  • Liver Cirrhosis - Companies Involved in Therapeutics Development
    • Conatus Pharmaceuticals Inc.
    • Digna Biotech, S.L.
    • Galectin Therapeutics, Inc.
    • Human Stem Cells Institute
    • Nimbus Therapeutics, LLC
    • Ocera Therapeutics, Inc.
    • Pharmicell Co., Ltd.
    • S-Evans Biosciences, Inc.
    • Stelic Institute & Co., Inc.
  • Liver Cirrhosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Cellgram-LC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DB-027 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DB-036 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emricasan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gemacell - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GXHPC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-654 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ornithine phenylacetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis and Pneumoconiosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Liver Cirrhosis and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STNM-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Liver Cirrhosis - Dormant Projects
  • Liver Cirrhosis - Discontinued Products
  • Liver Cirrhosis - Product Development Milestones
    • Featured News & Press Releases
      • May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
      • Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
      • Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting
      • Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
      • Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
      • Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
      • Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
      • Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting
      • Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement
      • May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam
      • Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
      • Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
      • Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension
      • Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Liver Cirrhosis, H2 2016
  • Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
  • Liver Cirrhosis - Pipeline by Digna Biotech, S.L., H2 2016
  • Liver Cirrhosis - Pipeline by Galectin Therapeutics, Inc., H2 2016
  • Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H2 2016
  • Liver Cirrhosis - Pipeline by Nimbus Therapeutics, LLC, H2 2016
  • Liver Cirrhosis - Pipeline by Ocera Therapeutics, Inc., H2 2016
  • Liver Cirrhosis - Pipeline by Pharmicell Co., Ltd., H2 2016
  • Liver Cirrhosis - Pipeline by S-Evans Biosciences, Inc., H2 2016
  • Liver Cirrhosis - Pipeline by Stelic Institute & Co., Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Liver Cirrhosis - Dormant Projects, H2 2016
  • Liver Cirrhosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Liver Cirrhosis, H2 2016
  • Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top